495 related articles for article (PubMed ID: 23706827)
1. Molecular analysis of changes in Pseudomonas aeruginosa load during treatment of a pulmonary exacerbation in cystic fibrosis.
Reid DW; Latham R; Lamont IL; Camara M; Roddam LF
J Cyst Fibros; 2013 Dec; 12(6):688-99. PubMed ID: 23706827
[TBL] [Abstract][Full Text] [Related]
2. Intravenous antibiotics reduce the presence of Aspergillus in adult cystic fibrosis sputum.
Baxter CG; Rautemaa R; Jones AM; Webb AK; Bull M; Mahenthiralingam E; Denning DW
Thorax; 2013 Jul; 68(7):652-7. PubMed ID: 23513028
[TBL] [Abstract][Full Text] [Related]
3. Antibiotic-resistant obligate anaerobes during exacerbations of cystic fibrosis patients.
Worlitzsch D; Rintelen C; Böhm K; Wollschläger B; Merkel N; Borneff-Lipp M; Döring G
Clin Microbiol Infect; 2009 May; 15(5):454-60. PubMed ID: 19196263
[TBL] [Abstract][Full Text] [Related]
4. Comparison of conventional and molecular methods for the detection of bacterial pathogens in sputum samples from cystic fibrosis patients.
van Belkum A; Renders NH; Smith S; Overbeek SE; Verbrugh HA
FEMS Immunol Med Microbiol; 2000 Jan; 27(1):51-7. PubMed ID: 10617790
[TBL] [Abstract][Full Text] [Related]
5. Reduction in Pseudomonas aeruginosa sputum density during a cystic fibrosis pulmonary exacerbation does not predict clinical response.
Lam JC; Somayaji R; Surette MG; Rabin HR; Parkins MD
BMC Infect Dis; 2015 Mar; 15():145. PubMed ID: 25887462
[TBL] [Abstract][Full Text] [Related]
6. Poor clinical outcomes associated with a multi-drug resistant clonal strain of Pseudomonas aeruginosa in the Tasmanian cystic fibrosis population.
Bradbury R; Champion A; Reid DW
Respirology; 2008 Nov; 13(6):886-92. PubMed ID: 18811887
[TBL] [Abstract][Full Text] [Related]
7. Bacterial cyanogenesis occurs in the cystic fibrosis lung.
Sanderson K; Wescombe L; Kirov SM; Champion A; Reid DW
Eur Respir J; 2008 Aug; 32(2):329-33. PubMed ID: 18480103
[TBL] [Abstract][Full Text] [Related]
8. Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response.
Ciofu O
APMIS Suppl; 2003; (116):1-47. PubMed ID: 14692154
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis.
Blumer JL; Saiman L; Konstan MW; Melnick D
Chest; 2005 Oct; 128(4):2336-46. PubMed ID: 16236892
[TBL] [Abstract][Full Text] [Related]
10. Changes in the lung bacteriome in relation to antipseudomonal therapy in children with cystic fibrosis.
Kramná L; Dřevínek P; Lin J; Kulich M; Cinek O
Folia Microbiol (Praha); 2018 Mar; 63(2):237-248. PubMed ID: 29127619
[TBL] [Abstract][Full Text] [Related]
11. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients.
Taccetti G; Campana S; Festini F; Mascherini M; Döring G
Eur Respir J; 2005 Sep; 26(3):458-61. PubMed ID: 16135728
[TBL] [Abstract][Full Text] [Related]
12. Increased airway iron as a potential factor in the persistence of Pseudomonas aeruginosa infection in cystic fibrosis.
Reid DW; Carroll V; O'May C; Champion A; Kirov SM
Eur Respir J; 2007 Aug; 30(2):286-92. PubMed ID: 17504792
[TBL] [Abstract][Full Text] [Related]
13. Long-term, low-dose azithromycin treatment reduces the incidence but increases macrolide resistance in Staphylococcus aureus in Danish CF patients.
Hansen CR; Pressler T; Hoiby N; Johansen HK
J Cyst Fibros; 2009 Jan; 8(1):58-62. PubMed ID: 18849202
[TBL] [Abstract][Full Text] [Related]
14. Is the improvement of CF patients, hospitalized for pulmonary exacerbation, correlated to a decrease in bacterial load?
Deschaght P; Schelstraete P; Van Simaey L; Vanderkercken M; Raman A; Mahieu L; Van Daele S; De Baets F; Vaneechoutte M
PLoS One; 2013; 8(11):e79010. PubMed ID: 24312174
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of adults with cystic fibrosis infected with antibiotic-resistant Pseudomonas aeruginosa.
Lechtzin N; John M; Irizarry R; Merlo C; Diette GB; Boyle MP
Respiration; 2006; 73(1):27-33. PubMed ID: 16113513
[TBL] [Abstract][Full Text] [Related]
16. Antibiotic perturbation of mixed-strain Pseudomonas aeruginosa infection in patients with cystic fibrosis.
Tai AS; Sherrard LJ; Kidd TJ; Ramsay KA; Buckley C; Syrmis M; Grimwood K; Bell SC; Whiley DM
BMC Pulm Med; 2017 Nov; 17(1):138. PubMed ID: 29096618
[TBL] [Abstract][Full Text] [Related]
17. Probiotic supplementation affects pulmonary exacerbations in patients with cystic fibrosis: a pilot study.
Weiss B; Bujanover Y; Yahav Y; Vilozni D; Fireman E; Efrati O
Pediatr Pulmonol; 2010 Jun; 45(6):536-40. PubMed ID: 20503277
[TBL] [Abstract][Full Text] [Related]
18. Molecular epidemiology of Pseudomonas aeruginosa, Burkholderia cepacia complex and methicillin-resistant Staphylococcus aureus in a cystic fibrosis center.
Campana S; Taccetti G; Ravenni N; Masi I; Audino S; Sisi B; Repetto T; Döring G; de Martino M
J Cyst Fibros; 2004 Aug; 3(3):159-63. PubMed ID: 15463902
[TBL] [Abstract][Full Text] [Related]
19. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone.
Regelmann WE; Elliott GR; Warwick WJ; Clawson CC
Am Rev Respir Dis; 1990 Apr; 141(4 Pt 1):914-21. PubMed ID: 2109558
[TBL] [Abstract][Full Text] [Related]
20. Pseudomonas aeruginosa antibiotic resistance in Australian cystic fibrosis centres.
Smith DJ; Ramsay KA; Yerkovich ST; Reid DW; Wainwright CE; Grimwood K; Bell SC; Kidd TJ
Respirology; 2016 Feb; 21(2):329-37. PubMed ID: 26711802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
